Background Beta-blockers remain one of the most frequently prescribed antihypertensive drug classes. The aim of the analysis was to evaluate characteristics of patients treated with beta-blockers and factors associated with the treatment of beta-blockers.
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Background
In the European Society of Hypertension/European Society of Cardiology (ESH/ESC) 2013 guidelines as well as in the guidelines of the Polish Society of Hypertension 2015, beta-blockers were maintained as a possible choice for antihypertensive treatment and were listed among five major antihypertensive drug classes [1] [2] [3] . However, some meta-analyses have reported that beta-blocker may be inferior to some other classes for the reduction of total mortality and cardiovascular events. Based on those data, some international guidelines did not include beta-blockers to the first-line antihypertensive treatment [4] [5] [6] .
Despite those controversies, recent surveys have shown that beta-blockers remain one of the most frequently used groups of antihypertensive drugs, second or third to the most popular renin-angiotensin system blockers. The rate of use of beta-blockers remained stable or even increased in surveys evaluating changes in the rate of use of antihypertensive medications over past decade [7] [8] [9] [10] .
The Pol-Fokus study aimed to evaluate characteristics of hypertensive patients in Poland and factors related to blood pressure (BP) control in a large sample of hypertensive patients treated for at least one year under the care of general practitioners (GPs) and specialists (cardiologists and hypertension specialists) all over Poland [11] . The aim of the presented analysis was to present clinical characteristics of hypertensive patients treated with beta blockers. We also analysed the prevalence of beta-blockers use in different subgroups of patients in which this class of antihypertensive drugs should be preferred and considered.
Material and methods
The methodology of the Pol-Fokus study was already published [11] . In summary, Pol-Fokus was a large, observational, cross-sectional survey of hypertensive subjects followed up by GPs, cardiologists and hypertension specialists throughout the Polish territory. The study was approved by the Ethics Committee of the Jagiellonian University, in Krakow, Poland and all participants provided informed consent. Nine hundred and seventy-eight GPs and 286 specialists (cardiology or hypertensiology) from all provinces in Poland participated in the Pol-Fokus study. The methods of selection of this group has been already described in details [11] .
The Pol-Fokus study included hypertensive patients meeting the following criteria: age 18 years or more, hypertension treated for at least one year, with at least one visit to the doctor, participating in the study over the last year. They had to be free from any acute disease in the preceding 4 weeks and free from known secondary causes of hypertension. After discarding data from doctors who did not achieve the specific quota or who provided incomplete questionnaires, as well as patients who were included despite not meeting the inclusion criteria and patients with no data regarding antihypertensive treatment, we finally analysed data from 12,375 patients [11] .
All patients underwent standard clinical evaluation. The known duration of the hypertension was recorded. Weight and height as well as waist circumference were measured. Body mass index (BMI) was calculated. Abdominal obesity was defined as a waist circumference > 102 cm and > 88 cm, for women and men respectively [2, 12] . Current antihypertensive medications were also documented. Plasma sodium, potassium, glucose, creatinine and total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol and triglycerides concentration, history of coronary artery disease (CAD), previous myocardial infarction, heart failure, arrhythmias, cerebrovascular diseases (CVD, including previous transient ischemic attack or stroke), asthma or chronic obstructive pulmonary disease (COPD), depression or anxiety, diabetes and other diseases were assessed. Each participating doctor was provided with specific instruction for these assessments. The estimated glomerular filtration rate (eGFR) was calculated according to the Modification of Diet in Renal Disease (MDRD) study formula [13] . Cardiovascular risk (stratification into 4 groups: low, moderate, high and very high added risk) as well as metabolic syndrome were evaluated according to the criteria of the 2013 ESH/ESC guidelines [2] .
BP was measured with a patient in the sitting position after a 5 min rest. Based on upper arm circumference, an appropriately sized cuff was placed on the arm with the lower edge of the cuff 2 cm above the antecubital fossa. Three consecutive readings were performed. The average of these three readings was recorded. Each participating doctor was provided with detailed instruction for BP measurement. Use of devices with proofed accuracy was recommended.
We defined hypertension control as BP levels both lower than 140 mm Hg for systolic and lower than 90 mm Hg for diastolic blood pressure [2] .
Data analysis was carried out using the statistical software PASW Statistics 18 (SPSS Inc., Chicago, IL, USA). The results are presented as mean ± one stan- Multivariate logistic regression models were performed, in order to determine the combined effect of several variables on the prevalence of the characteristic. For multivariate analysis the variables with significant association were included. Multicollinearity was checked by variation inflation factor. P < 0.05 was considered statistically significant.
Results
As described previously, we included 12,375 patients (mean age 64.0 ± 12.3 years; age range 18-98 years; 59% females) [11] . Overall, 7080 patients (57.2% of the whole group) were treated with beta-blockers. Among 5 major classes of antihypertensive drugs beta-blockers were the second most frequently used antihypertensive group after angiotensin converting enzyme (ACE) inhibitors (61.3% of the whole group) and before thiazide/thiazide-type diuretics, calcium channel blockers and angiotensin II receptor blockers (ARBs) (respectively: 48.0%, 36.5% and 35.3%). Among hypertensive patients on monotherapy beta-blockers were the third most frequently used antihypertensive group after ACE inhibitors and ARBs ( Figure 1 ).
Patients treated with beta-blockers were characterized by higher: age, BMI, frequency of abdominal obesity, pulse pressure, median number of antihypertensive drugs, plasma concentrations of triglycerides and glucose and lower concentrations of total and LDL cholesterol as well as by lower eGFR (Table 1) . There were no differences between patients treated with beta-blockers and not treated with beta-blockers in systolic and diastolic BP level and in the rate of hypertension control as well as in plasma concentration of sodium, potassium, HDL cholesterol, and creatinine (Table 1) .
We analysed the rate of use of beta-blockers in 3 age categories (40 years and less, 40-65 years and 65 years and more) ( Figure 2 ). Overall, beta-blockers were used more frequently in the 40-65 years and 65 and more years groups. Among patients on monotherapy there was no difference in the rate of use of beta-blockers among the three age groups. Among patients on 2 antihypertensive drugs beta-blockers in combination with renin-angiotensin blockers were used most frequently in the 40-65 years group. Among patients on 3 antihypertensive drugs, the combination of a beta-blocker, a renin-angiotensin blocker and a thiazide/thiazide-type diuretic was used more frequently in the 40 years and less group and in the 40-65 years group ( Figure 2 ). Among age categories 40-65 years and 65 years and more, beta-blockers were used more frequently in patients with high and very high cardiovascular risk than in patients with low and moderate cardiovascular risk. Among patients 40 years and less, the rate of use of beta-blockers was not related to the cardiovascular risk level (Figure 3 ).
The rate of use of beta-blockers was higher in patients with metabolic syndrome, diabetes, coronary artery disease, previous myocardial infarction, heart failure, arrhythmias, cerebrovascular disease and eGFR lower than 60 ml/min/1,73 m 2 than in patients without those conditions ( Figure 4 ). Beta-blockers were used less frequently among patients with asthma/COPD than without asthma/ /COPD (54.0 vs 58.0%; p = 0.017). Among patients with anxiety/depression, the rate of use of beta-blockers was higher than among patients without anxiety/depression (62.1% vs 56.6%; p < 0.001).
Rate of specific conditions in which beta-blockers might be preferred: heart failure, previous myocardial infarction (without heart failure), arrhythmias (excluding patients with heart failure and previous myocardial infarction) and coronary artery disease (excluding patients with heart failure, previous myocardial infarction and arrhythmias) in all patients treated with beta-blockers and in patients treated with be- ACEi -angiotensin converting enzyme inhibitor, ARB -angiotensin II receptor blocker, BB -beta--blocker, CCB -calcium channel blocker, n -number of patients, TD -thiazide/thiazide-type diuretic www.ah.viamedica.pl ta-blockers across the age categories < 40 years, 40-65 years and ≥ 65 years were evaluated ( Figure 5 ). In all patients treated with beta-blockers the most frequent conditions were coronary artery disease and heart failure ( Figure 5A ). In patients aged 40 years and younger, those conditions were found only in 21.7% of patients ( Figure 5B ). In patients aged 40-65 years, the most frequent conditions were coronary artery disease and arrhythmias, however none of the listed above conditions was found in 41.3% of patients ( Figure  5C ). In older patients treated with beta-blockers, the most frequent conditions were coronary artery disease, previous myocardial infarction and heart failure present in 70.1% of patients ( Figure 5D ).
www.ah.viamedica.pl Figure 5 . Rate of specific conditions in which beta-blockers might be preferred: heart failure, previous myocardial infarction (without heart failure), arrhythmias (excluding patients with heart failure and previous myocardial infarction) and coronary artery disease (excluding patients with heart failure, previous myocardial infarction and arrhythmias) in all patients treated with beta-blockers (A) and in patients treated with beta-blockers across the age categories < 40 years (B), 40-65 years (C) and ≥65 years (D)
We performed multivariate models (including gender, age, pulse pressure, abdominal obesity, metabolic syndrome, diabetes, coronary artery disease, previous myocardial infarction, heart failure and arrhythmias) to assess independent association of factors with the treatment with beta-blockers in the whole studied group and across the age categories < 40 years, 40-65 years and 65 years and more. Only abdominal obesity or metabolic syndrome and arrhythmias were independently associated with beta-blockers use in the whole group and across all age categories (Table 2) . Coronary artery disease and previous myocardial infarction were associated independently with beta-blockers use in patients 40-65 years and in patients 65 year and more. In the latter group also heart failure was independently associated with beta-blockers use.
Discussion
Beta-blockers have long been used as a first-line therapy for hypertension because they were thought to have long-term favourable effects on all-cause and cardiovascular mortality, but the robustness of the evidence for initiating antihypertensive therapy with beta-blockers has been challenged [14] . Moreover as summarized by the ESH/ESC 2013 guidelines, none of the preferred 2 drugs combination is based on beta-blockers. Although the thiazide diuretic-beta-blocker combination has been shown to be effective in cardiovascular risk reduction, this combination appears to elicit more cases of new-onset diabetes in susceptible individuals, compared with other combinations. Therefore this combination has been described as "useful combination (with some limitations)" [2, 15] . However Polish Society of Hypertension 2015 guidelines listed two combinations containing a beta-blocker (with an ACE inhibitor or a calcium channel blocker) as preferred combinations [3] .
Our study showed that despite those concerns the rate of use of beta-blockers in Poland remains relatively high (57.2%) and this group of antihypertensive drugs remains one of the most often selected antihypertensive medication classes used for the treatment of hypertension only second to renin-an-www.ah.viamedica.pl Table 2 . Multivariate model assessing independent association of factors with the treatment with beta-blocker in the whole studied group and across the age categories < 40 years, 40-65 years and ≥ CI -confidence interval; OR -odds ratio, 1 -for 10 years increase, 2 -for 10 mm Hg increase giotensin blockers (ACE inhibitors and ARBs). Beta-blockers were used more frequently in polytherapy regimens than in monotherapy. The recent data from German Health Examination Surveys showed high rate of beta-blockers use, rising from 39% in 1998 to 54% in 2008-2011 [7] . In the evaluation of the United States National Health and Nutrition Examination Survey (NHANES), the overall prevalence of use of beta-blockers increased from 20.3% in NHANES 2001 to 2002 to 31.9% in NHANES 2009 to 2010 (the rates were given for all hypertensive patients -both treated and untreated). This was mainly driven by a 65% increase in the use of beta-blockers used in polytherapy regimens to treat hypertension [10] . Also other studies showed similar trends for beta-blocker use in hypertensive patients [8, 9] . Beta-blockers are recommended when hypertension is associated with certain compelling co-morbidities. In post-myocardial infarction setting, beta-blockers decrease recurrent myocardial infarction and improve survival. They have been also shown to improve functional class, reduce frequency of hospitalization and improve survival in patients with heart failure [14] . In our studies those conditions were found in respectively 21% and 11% of patients on beta-blockers. Moreover, respectively 82% and 73% of patients with those conditions were taking beta-blockers. Thus we showed high utilization of this group in conditions where benefits of beta-blocker are proven. Our results also underline that patients with hypertension are characterized by pronounced cardiovascular burden and frequent concomitant cardiovascular disease requiring beta-blockers' use.
years

All patients
Our study showed that the rate of use of beta-blockers in patients with asthma/COPD was lower than in patients without these conditions. Historically, beta-blockers have sometimes been withheld from asthma or COPD patients. Taking into account that most of the patients in this group in our study had COPD, it should be noted that several studies including COPD and beta-blocker treatment found a protective effect of beta-blockers on all-cause mortality both in primary or secondary prevention [16] . Thus emphasis should be placed on higher awareness of benefits of beta-blocker treatment in patients with COPD. Nevertheless, these agents should be used with caution in patients with pulmonary disease [14] .
There is concern that beta-blockers may impair glycaemic control by reducing insulin sensitivity and mask hypoglycaemia. However, beta-blockers may produce greater improvements in cardiovascular outcome among diabetic patients compared with those without diabetes. Treatment with third-generation www.ah.viamedica.pl beta-blockers does not appear to be associated with changes in glycaemic control and may improve insulin sensitivity [14, 17] . We found that the rates of use of beta-blockers were higher both in patients with diabetes or metabolic syndrome as compared with patients without those symptoms. Although we were not able to differentiate which particular agents were used, current guidelines advise that additional receptor mediated effects (alpha1-adrenergic receptor blockade by carvedilol, beta3-adrenergic receptor activation by nebivolol), beneficial effects on metabolic parameters and endothelial function, and the results of large-scale clinical trials all suggest that vasodilating beta-blockers should be preferred if a beta-blocker is indicated in hypertensives with diabetes or metabolic syndrome [3] .
Beta-blockers are the drugs of first choice for the treatment of hypertension in patients with coronary artery disease that causes angina [18] . However, no large trails have been performed to assess their effectiveness in reducing major cardiac events in patients with stable coronary disease without prior myocardial infarction. In a large study based on evaluation of electronic health records, it has been shown that use of beta-blockers among patients with new-onset coronary artery disease was associated with lower risk of cardiac events only among patients with a recent myocardial infarction [19] . Also in the post hoc analysis from the Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilization, Management, and Avoidance (CHARISMA) trial showed that beta-blocker use is not associated with lower cardiovascular events in those with coronary artery disease without prior myocardial infarction, with suggestion of inferior outcome with regard to stroke risk [20] . However, these findings have not been conferred in the guidelines [1] [2] [3] . In our study, stable coronary artery disease without prior myocardial infarction was the most frequent compelling indication for the utilization of beta-blockers. This finding in the light of uncertain cardioprotective effect emphasize the need of further studies aimed on evaluation of these agents benefits in patients with stable coronary artery disease without prior myocardial infarction.
The anti-arrhythmic properties result from decreased sympathetic and heart rate activity and increased cardiac vagal tone. According to current guidelines, use of beta-blockers in the treatment of hypertension is recommended in patients with arrhythmias [2, 3, 14] . Our study showed high utilization of these agents in patients with arrhythmia as well as that arrhythmias remain a compelling indication for use of these agents in hypertensive subjects, especially younger than 40 years and in the age group of 40-65 years.
The use of beta-blockers remains the subject of debate. They are no more effective than other antihypertensive agents and, according to some recent analysis, they failed to reduce myocardial infarction while providing less protection against strokes. This is particularly true for atenolol [21] [22] [23] . Nevertheless, the current Polish Society of Hypertension guidelines upheld the position taken in the previous guidelines that beta-blockers should remained among first-line antihypertensive drugs, stressing that that vasodilating agents (carvedilol, nebivolol) due to their haemodynamic properties (smaller negative chronotropic effect and a reduction of total peripheral resistance), resulting in a more favourable effect on central aortic pressure, should be preferred among beta-blockers in patients with uncomplicated hypertension. This has been also reflected in the text of the 2013 ESH/ /ESC guidelines that noted some beneficial aspects of the mechanism of action of vasodilating beta-blockers [1] [2] [3] . Our study showed high rate of patients on beta-blockers with none of the compelling indications discussed above in younger patient but not in older patients (especially those over 65 years). In patients older than 40 years use of beta-blockers was related to the level of cardiovascular risk it was not true for patients younger than 40 in whom no relation between level of cardiovascular risk and utilization of these agents was found. Although we were not able to assess the particular drugs used, more emphasis should be put on the use of vasodilating beta-blockers in younger patients in whom beta-blockers are frequently used with none of the compelling indications present.
Conclusions
Our study based on a large group of treated hypertensive patients has shown high utilization rate of beta-blockers in patients with hypertension, only second to renin-angiotensin blockers. In middle age and, especially, in older patients it might reflect high cardiovascular burden of those patients, including coexistence of established cardiac disease. In younger patients beta-blockers are used more frequently with none of the compelling indications present.
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